The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.

• The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching.
• There could be reduced demand for junk food and increased demand for athletic brands.
• These are the stock market's potential winners and losers of the fast-growing weight loss drugs.

The rise of GLP-1 weight loss drugs like Ozempic, Wegovy, and Mounjaro are poised to send shock waves through the stock market.

Tens of millions of Americans could collectively shed billions of pounds as indications for these drugs are potentially expanded from only diabetes and overweight patients to those who suffer from sleep apnea, heart conditions, or even addictions.